Eli Lilly to Invest $6.5 Billion in New Houston Facility to Boost Production of Oral Weight-Loss Drug Orforglipron

Intelligent Finance APP learned that pharmaceutical giant Eli Lilly (LLY.US) announced on Tuesday that it would invest $6.5 billion inUnited StatesHouston, Texas, is building a brand-new production facility to expand its small molecule drug manufacturing capacity, with a focus on producing the highly anticipated experimental oral weight-loss drug orforglipron.

This will be Eli Lilly's second major investment plan announced this year. As early as February this year, Eli Lilly announced plans to invest at least $27 billion in building four new manufacturing plants in the U.S. Since 2020, the company's cumulative investment in domestic production in the U.S. has reached $23 billion. Eli Lilly stated that the locations of the remaining two plants will be announced this year, with all four plants expected to be fully operational within the next five years.

As demand for weight-loss drugs surges in the U.S., Eli Lilly and its competitor Novo Nordisk's (NVO.US) GLP-1 class of weekly injectable medications have faced supply shortages. The oral formulation orforglipron is considered a key product for the company to maintain its market dominance.

Eli Lilly CEO David Ricks stated, "The new Houston facility will significantly enhance the scalability of orforglipron production and, following drug approval, help address the treatment needs of tens of millions of patients with obesity and type 2 diabetes worldwide. Compared to injectable formulations, oral medications offer greater convenience as they do not require dietary or fluid restrictions."

Industry insiders pointed out that the GLP-1 drug market is growing rapidly, and oral formulations can not only address capacity shortages but also further expand the potential patient population.

Eli Lilly's move is also a positive response to the threat of the latest tariff policy by U.S. President Trump. Trump previously stated that tariffs might be imposed on drugs imported into the U.S. to push pharmaceutical companies to relocate their production back to the United States. Over the past decade, the scale of the domestic drug manufacturing industry in the U.S. has significantly shrunk.

Analysts believe that Eli Lilly's expansion of its production capacity in the United States is not only to meet market demand but also to reduce supply chain risks brought about by policy uncertainties.

According to the company's announcement, the new Houston facility will primarily produce orforglipron and other small-molecule drugs targeting cardiometabolic health, oncology, immunology, and neuroscience. Small-molecule drugs typically come in the form of oral tablets, which are not only more convenient for patients to use but also easier to mass-produce, with relatively lower manufacturing costs.

Eli Lilly stated that the project will bring 615 full-time jobs to the Greater Houston area, including engineers, scientists, operations staff, and laboratory technicians, while creating 4,000 construction-related jobs during the construction process.